Marcellus M. van der Hulst;Paulus A.J. Link;Gerhard-Wilhelm Bielenberg;Cornelis R. van den Akker
发明人:
Paulus A.J. Link,Marcellus M. van der Hulst,Gerhard-Wilhelm Bielenberg,Cornelis R. van den Akker
申请号：
US13565872
公开号：
US20120302555A1
申请日:
2012.08.03
申请国别(地区):
US
年份:
2012
代理人:
摘要：
The disclosed invention relates to a method of treatment of a disorder modulated by blocking angiotensin II (AII) receptors, and particularly selected from the group consisting of hypertension, congestive heart failure, renal failure, and combinations thereof, by administering to a subject in need thereof an effective dose of an eprosartan compound. With reference to the Recommended Effective Daily Dose of 600 mg, calculated on the basis of eprosartan administered in the form of eprosartan mesylate, it has now been found that a lower dose of eprosartan can be administered when the eprosartan compound is eprosartan acid. This dose is in the range of from 410 to 490 mg, most preferably about 450 mg.
